Valuation: Sera Prognostics, Inc.

Market Cap 83.24M 73.04M 68.98M 62.87M 118M 7.98B 119M 826M 320M 4.08B 313M 306M 13.1B P/E 2026 *
-3.21x
P/E 2027 * -3.94x
Enterprise Value 83.24M 73.04M 68.98M 62.87M 118M 7.98B 119M 826M 320M 4.08B 313M 306M 13.1B EV / Sales 2026 *
370x
EV / Sales 2027 * 43.2x
Free-Float
85.71%
Yield 2026 *
-
Yield 2027 * -
1 day-3.32%
1 week-2.16%
Current month-3.77%
1 month-6.42%
3 months+13.33%
6 months+2.51%
Current year-30.85%
1 week 2
Extreme 2
2.2
1 month 1.96
Extreme 1.9603
2.2
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
12.36
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 2023-05-31
Director of Finance/CFO 47 2026-08-30
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Chairman 74 2011-04-19
Chairman 58 2023-06-07
Director/Board Member 59 2011-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/10/26 Sell

Chief Executive Officer

-7,022 0.0182%
9/10/26 Sell

General Counsel

-2,190 0.0057%
9/10/26 Sell

Chief Technology Officer

-486 0.0013%
Change 5-day change 1-year change 3-year change Capi.($)
-3.32%-2.16%-30.85%+14.61% 83.24M
+0.04%+1.24%+17.01%+21.34% 22.51B
-3.16%-1.51%+11.39%-22.19% 3.6B
-3.63%-1.19%+46.51%+54.57% 3.36B
-1.66%-1.29%-28.27%-35.00% 1.95B
+0.23%-1.88%-37.83% - 1.94B
-4.59%+0.74%+77.40%+120.45% 1.57B
+3.13%+6.72%-4.73%+22.86% 1.66B
-0.81%+2.22%-25.94%+6.97% 1.33B
-0.84%-0.12%+84.01%+194.25% 1.23B
Average -1.48%-0.08%+10.87%+41.99% 3.92B
Weighted average by Cap. -0.90%+0.39%+16.11%+26.63%

Financials

2026 *2027 *
Net sales 225K 197K 186K 170K 318K 21.57M 320K 2.23M 864K 11.02M 845K 827K 35.41M 1.92M 1.69M 1.6M 1.45M 2.72M 185M 2.74M 19.09M 7.39M 94.26M 7.23M 7.07M 303M
Net income -33.93M -29.78M -28.12M -25.63M -47.98M -3.25B -48.32M -337M -130M -1.66B -127M -125M -5.34B -29.1M -25.54M -24.12M -21.98M -41.14M -2.79B -41.44M -289M -112M -1.42B -109M -107M -4.58B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
26-09-25 US$2.040 -3.32% 12,771
26-09-24 US$2.110 +2.43% 5,357
26-09-23 US$2.060 -3.29% 13,907
26-09-22 US$2.130 +0.47% 10,410
26-09-21 US$2.120 +1.68% 17,003
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.110USD
Average target price
5.500USD
Spread / Average Target
+160.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock